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The joint ESC and EACTS guidelines help physicians in select-
ing the best management strategies for an individual patient
with valvular heart disease. The level of evidence and the
strength of recommendation are outlined in Tables 1 and 2.
The Czech Society of Cardiology endorses ESC guidelines and
prepares condensed summaries (a text of 5000 words plus
selected tables and figures) from the original full text. For
details and for references see the original ESC document.2. Introduction
The update of the guidelines on valvular heart disease
(VHD) was necessary for several reasons. There is new
evidence on risk stratification with the use of echocardiogra-
phy. The therapeutic options have changed due to further
development of surgical repair techniques of the valves and
new trans-catheter techniques.
The population with VHD is often of older age, polymorbid,
with growing proportion of previously operated patients. The
decision concerning treatment must be complex, made in
collaboration between cardiologists and cardiac surgeons. TheEuro Heart Survey on VHD confirmed a real gap between older
guidelines and their application in real life. Due to the lack of
evidence-based data and randomized studies, most recommen-
dations in VHD are the result of expert consensus opinion
(Tables 1 and 2).3. General comments
Decision-making should be made by a ‘‘heart-team’’ with
expertise in VHD, including cardiologists, cardiac surgeons,
imaging specialists, anaesthetists, intensive care specialists
and other. The ‘‘heart-team’’ approach is advisable especially
for high-risk patients on one side and asymptomatic patients
on the other side, where the valve reparability is a key-
component in decision-making. The most important ques-
tions in decision making are summarized in Table 3.
3.1. Patient evaluation
Clinical evaluation plays a major role in the assessment of
symptoms, lifestyle, change of activities and comorbidities. The
development of symptoms is often a driving indication for
intervention. Therefore, patients who currently deny symptoms,
Table 3 – Essential questions in the evaluation of a patient for valvular intervention.
Is valvular heart disease severe?
Does the patient have symptoms?
Are symptoms related to valvular disease?
What are patient life expectancya and expected quality of life?
Do the expected benefits of intervention (vs spontaneous outcome) outweigh its risks?
What are the patient’s wishes?
Are local resources optimal for planned intervention?
a According to age, gender, comorbidities and country-specific life expectancy.
Table 4 – Echocardiographic criteria for the definition of severe valve stenosis.
Aortic stenosis Mitral stenosis Tricuspid stenosis
Valve area (cm2) o1 o1
Indexed valve area (cm2/m2 BSA) o0.6
Mean gradient (mm Hg) 440a 410b Z5
Maximum jet velocity (m/s) 44a
Velocity ratio o0.25
a In patients with normal cardiac output.
b Useful in patients in sinus rhythm, to be interpreted according to heart rate.
Table 2 – Levels of evidence.
Level of evidence A Data derived from multiple randomized clinical trials or meta-analyses.
Level of evidence B Data derived from a single randomized clinical trial or large non-randomized studies.
Level of evidence C Consensus of opinion of the experts and/or small studies, retrospective studies, registries.
Table 1 – Classes of recommendations.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 1 – e 5 6 e43but have been treated for heart failure or have decreased their
daily activities due to symptoms, should be classified as sympto-
matic. Physical examination, evaluation of the murmur or
change of the murmur, ECG and X-ray is essential.Echocardiography is a keymethod for the assessment of valve
disease severity (Tables 4 and 5). Valve area is the most important
parameter for the evaluation of stenosis severity. Pressure gra-
dient and jet velocity are flow dependent. For the evaluation of
Table 5 – Echocardiographic criteria for the definition of severe valve regurgitation.
Aortic regurgitation Mitral regurgitation Tricuspid regurgitation
QUALITATIVE
Valve morphology Abnormal/flail/large
coaptation defect
Flail leaflet/ruptured papillary muscle/large
coaptation defect
Abnormal/flail/large
coaptation defect
Colour flow regurgitant
jet
Large in central jets Very large central jet or eccentric jet adhering,
swirling, and reaching the posterior wall of the left
atrium
Very large central jet or
eccentric wall
impinging jeta
Variable in eccentric
jetsa
CW signal of regurgitant
jet
Dense Dense/triangular Dense/triangular with
early peaking
Other Holodiastolic flow
reversal in descending
aorta, end-diastolic
velocity 420 cm/s
Large flow convergence zone
SEMIQUANTITATIVE
Vena contracta width 46 mm Z7 mm Z7 mma
Upstream vein flow – Systolic pulmonary vein flow reversal Systolic hepatic vein
flow reversal
Inflow – E wave dominant Z1.5 m/s E wave dominant
Z1 m/s
Other Pressure half-time
o200 ms
TVI mitral/TVI aortic 41.4 PISA radius 49 mmb
QUANTITATIVE Primary secondary
EROA (mm2) Z30 Z40 Z20 Z40
R Vol (ml/beat) Z60 Z60 Z30 Z45
Enlargement of cardiac
chambers
Left ventricle Left ventricle, left atrium Right ventricle, right
atrium, inferior vena
cava
CW: Continuous wave, TVI: time–velocity integral, PISA: proximal isovelocity surface area, EROA: effective regurgitant orifice area,
R Vol: regurgitant volume.
a At Nyquist limit of 50–60 cm/s.
b Baseline Nyquist limit shift of 28 cm/s.
Table 6 – Management of coronary artery disease in
patients with valvular heart disease.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 1 – e 5 6e44valve regurgitation effective regurgitant orifice area (EROA) and
vena contracta (VC) are less flow-dependent than colour Doppler
jet size. All quantitative evaluations have limitations, possible
errors and are highly operator-dependent.
Echocardiography is a key method for the assessment of
the possibility of surgical valve repair and transcatheter
intervention. Indices of left ventricular enlargement and
function are strong prognostic factors. The use of indexed
values to body surface area (BSA) should be used in patients
with small body size, but may be misleading in patients with
severe obesity (body mass index 440 kg/m2).
Stress testing is useful for unmasking symptoms and risk
stratification in aortic stenosis (AS). Stress echocardiography
reveals the degree of mitral regurgitation (MR), aortic gradi-
ents or exercise pulmonary hypertension (PH).
Other important non-invasive tests comprise cardiac mag-
netic resonance, computed tomography, fluoroscopy, and
radionuclide angiography. There is an increasing evidence
of the usefulness of biomarkers (B natriuretic peptide) for
prognosis assessment.
Coronary angiography is indicated for the detection of asso-
ciated coronary artery disease (CAD) in patients with VHD before
surgery (Table 6). Cardiac catheterization should be performed in
the case of inconclusive or discordant non-invasive evaluation.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 1 – e 5 6 e45The degree of comorbidities should be evaluated (chronic
obstructive pulmonary disease, renal and hepatic dysfunc-
tion, cognitive and functional capacities).3.2. Endocarditis prophylaxis
Antibiotic prophylaxis should be considered for high-risk pro-
cedures in high-risk patients. E.g., patients with prosthetic
heart valves or prosthetic material used for valve repair or in
patients with previous endocarditis or congenital heart disease,
according to the current ESC guidelines. The general role of
prevention is very important in all patients with VHD including
good oral hygiene and aseptic measures during catheter
manipulation or any other invasive procedure.3.3. Prophylaxis for rheumatic fever
In patients with rheumatic heart disease, long-term prophylaxis
against rheumatic fever is recommended, using penicillin for at
least 10 years after the last episode of acute rheumatic fever, or
until 40 years of age, whichever is the longest.3.4. Risk stratification
Several registries have shown that therapeutic interventions
are underused in high-risk patients with symptoms. Patient
transfer to a more specialised centre should be considered for
specialised procedures such as complex valve repair.Table 7 – Indications for surgery in A-severe aortic regurgitatio
regurgitation).3.5. Management of associated conditions—arrhythmias
Oral anticoagulation with target international normalised ratio
(INR) 2–3 is recommended in patients with native VHD and any
type of atrial fibrillation (AF). The substitution of vitamin K
antagonists by new agents is not recommended, because
specific trials in patients with VHD are not available. In patients
undergoing valve surgery, surgical ablation should be consid-
ered in those with symptomatic AF and may be considered in
asymptomatic AF, if feasible with minimal risk. The decision
should be individualised according to the age, duration of AF
and left atrial size. Cardioversion should be attempted soon
after successful intervention in the case of AF recurrence.4. Aortic regurgitation (AR)
AR can be caused by primary disease of the aortic leaflets
and/or abnormalities of the aortic root geometry. Congenital
abnormalities, mainly bicuspid morphology are frequent
findings.
Patients with acute severe AR, mostly due to infective
endocarditis or aortic dissection, have a poor prognosis
without intervention, due to the hemodynamic instability.
Patients with chronic severe AR have a poor long-term
prognosis if symptoms are present. Mortality in symptomatic
patients with severe AR without surgical treatment may be
10–20% per year. In asymptomatic patients, the probability
of adverse events is low as long as the left ventricle (LV) is
not dilated and has normal systolic function. When LVn and B-aortic root disease (whatever the severity of aortic
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 1 – e 5 6e46end-systolic diameter is 450 mm, the probability of death,
symptoms or LV dysfunction is reported to be 19% per year.
In Marfan syndrome, the strongest predictors of death
or aortic complications are the root diameter and family
history of acute cardiovascular events. In patients with
bicuspid aortic valve there is a high prevalence of ascending
aortic dilatation. It is currently less clear whether the like-
lihood of aortic complications is increased, compared to
patients with a tricuspid aortic valve of a similar size.
Indication for aortic valve surgery is severe symptomatic
AR (including NYHA class II) or severe asymptomatic AR with
LV dilatation or LV dysfunction. Aortic rootZ55 mm indicates
that the surgery should be performed irrespective of the
degree of AR. Lower thresholds are used for Marfan syndrome
and bicuspid aortic valve (Table 7, Fig. 1).
4.1. Results of surgery
Valve replacement remains the most widely used technique,
but the proportion of valve repair procedures is increasing in
experienced centres. Operative mortality is low (1–4%) for
both techniques. With advanced age and the need for con-
comitant CABG the operative mortality increases to 3–7%.
The strongest predictors of operative mortality are older age,
higher preoperative functional class, LVEFo50% and
LVESD450 mm. Aortic root surgery with reimplantation of
coronary arteries has slightly higher mortality than isolated
valve surgery. In young patients, combined treatment of
aneurysm of the ascending aorta with either valve preserva-
tion or replacement can be performed in expert centres with
a very low mortality rate.
4.2. Medical therapy
Vasodilators and inotropic agents may be used for short-term
therapy to improve the condition of patients with severe
heart failure (HF) before aortic valve surgery. In individuals
with chronic severe AR and HF, vasodilators (angiotensin-
converting enzyme—ACE, inhibitors or angiotensin receptor
blockers—ARBs) are useful in the presence of hypertension,
when surgery is contraindicated, or if LV dysfunction
persists postoperatively. A positive effect of these agents,Fig. 1 – Management of aortic regurgitation.(or dihydropyridine calcium channel blockers), in asympto-
matic patients without hypertension in order to delay surgery
is unproven.
In patients with Marfan syndrome, beta-blockers may slow
down aortic root dilatation and reduce the risk of aortic compli-
cations and should be considered before and after surgery.
Preliminary findings suggest that selective ARBs have an
intrinsic effect on the aortic wall by preserving elastin fibres.
Their clinical benefit remains to be proven by ongoing trials.
Patients with Marfan syndrome, or others with borderline
aortic root diameters approaching the threshold for interven-
tion, should be advised to avoid strenuous physical exercise,
competitive, contact, and isometric sports.5. Aortic stenosis (AS)
AS has become the most frequent VHD in Europe and North
America. Calcific AS presents 2–7% of the population over
65 years.
Echocardiography is the key diagnostic tool. However,
transvalvular pressure gradients are flow-dependent and
valve-area measurements are operator-dependent. The
majority of severe AS presents with high gradients; however
in the presence of low flow, low pressure gradient may be
found even in severe AS. Low dose dobutamine test may
distinguish severe AS from pseudosevere (mild or moderate)
AS with LV dysfunction. In truly severe AS, aortic valve area
(AVA) o1 cm2 remains small during low dose dobutamin
infusion and the gradient increases; in pseudosevere AS the
AVA increases. If depressed LVEF is caused predominantly by
excessive afterload (afterload mismatch), LV function usually
improves after surgery. Severe AS with AVAo1 cm2 and low
pressure gradient (mean gradient o40 mm Hg) may be also
present in patients with preserved LVEF. These patients are
typically elderly, with the history of hypertension, small
ventricles with marked hypertrophy and low stroke volume
index o35 ml/m2.
Exercise testing is contraindicated in symptomatic
patients with AS, but it provides important data for the
indication of intervention in asymptomatic patients with
severe AS, particularly in physically active patients younger
than 70 years.
When hypertension is present, the severity of AS should
be reassessed when patient is normotensive.
Sudden cardiac death is frequent in symptomatic patients,
but appears to be rare in truly asymptomatic patients with
severe AS (o1%/year). As soon as symptoms occur, the
prognosis of severe AS is dismal with survival rates of only
15–50% at 5 years. Patients should be instructed to report
symptoms as soon as they develop.
Indications for aortic valve replacement are summarized
in Table 8.
Concomitant aneurysm/dilatation of the ascending aorta
requires the same treatment as in aortic regurgitation (Table 7B).
5.1. Results of surgery
Operative mortality of isolated AVR is 1–3% in patients
younger than 70 years and 4–8% in older patients. After
Table 8 – Indications for aortic valve replacement (AVR) in aortic stenosis.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 1 – e 5 6 e47successful AVR symptoms and quality of life are improved
and long-term survival is similar to age-matched population
in older patients. Surgery has been shown to prolong and
improve the quality of life in selected patients over 80 years.
Age, per se, should not be considered a contraindication for
surgery. In younger patients the long-term survival may be
lower compared to age-matched population, but substantially
better compared to conservative treatment.
5.2. Balloon valvuloplasty (BVP)
BVP plays important role in paediatric population with con-
genital AS. In adults the role of BVP alone is limited because
of low efficacy, high rate of complications (410%) and very
high rate of restenosis and clinical deterioration within 6–12
months. It may be considered as a bridge to surgery or TAVI in
haemodynamically unstable patients or before urgent major
non-cardiac surgery in patients with symptomatic severe AS
(class IIb, level of evidence C).5.3. Transcatheter aortic valve implantation (TAVI)
In patients with high surgical risk, TAVI has been shown to be
feasible (procedural success 490%) using transfemoral,
transapical or, less commonly subclavian or direct trans-
aortic approach. Reported 30-days mortality is 5–15%. The
main procedure related complications are stroke (1–5%), need
for new pacemaker (up to 7% for balloon-expanded system
and up to 40% for the self-expanded system) and vascular
complications (up to 20%). Paravalvular regurgitation is com-
mon, usually trace or mild. Immediate cardiac surgery for
life-threatening complications is required in 1–2% of TAVI.
One-year survival for TAVI ranges from 60% to 80%, depend-
ing on the severity of comorbidities. Patients not suitable for
surgical AVR clearly benefit from TAVI (1-year mortality 31%
vs 51% and significant symptomatic improvement). The first
randomized trial PARTNER comparing TAVI and surgical AVR
in high-risk but operable patients showed TAVI to be non-
inferior for all-cause 1-year mortality and functional
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 1 – e 5 6e48improvement. Indications and contraindications for TAVI are
given in Tables 9 and 10.
Among high-risk patients who are still candidates for
surgery, the decision between surgery or TAVI should beTable 9 – Recommendations for the use of transcatheter
aortic valve implantation (TAVI).
Table 10 – Contraindications for transcatheter aortic valve imp
ABSOLUTE CONTRAINDICATIONS
Absence of a heart team and no cardiac surgery on the site
Appropriateness of TAVI as an alternative to AVR, not confirmed by a he
Clinical
– Estimated life expectancy o1 year
– Improvement of quality of life unlikely because of comorbidities
– Severe primary associated disease of other valves with major contribu
Anatomical
– Inadequate annulus size (o18 mm, 429 mm)—for current devices
– Thrombus in the left ventricle
– Active endocarditis
– Elevated risk of coronary ostium obstruction (asymmetric valve calcific
aortic sinuses)
– Plaque with mobile thrombi in the ascending aorta, or arch
– For transfemoral/subclavian approach: inadequate vascular access (ve
RELATIVE CONTRAINDICATIONS
Bicuspid or non-calcified valve
Untreated coronary artery disease requiring revascularisation
Haemodynamic instability
LVEFo20%
For transapical approach: severe pulmonary disease, LV apex not accessindividualized by a heart team with respect to advantages
and disadvantages of both techniques. The use of the SCORE
is known to markedly overestimate the operative mortality.
Use of the STS score >10% may result in more realistic
assessment of operative risk. On the other hand frailty,
porcelain aorta, history of chest radiation or patent coronary
bypass grafts make patients less suitable for surgery even
with Euro-SCOREo20%. The risk assessment should mostly
rely on the clinical judgment of the heart team.
5.4. Medical therapy
Symptomatic patients require intervention; no medical ther-
apy for AS is able to improve the outcome. Maintenance of
sinus rhythm is important. Co-existing hypertension should
be treated with careful titration to avoid hypotension. Ran-
domized trials did not prove that statins affect the progres-
sion of AS. On the other hand modification of atherosclerotic
risk factors must be recommended following the guidelines.
5.4.1. Combination of severe AS with mitral regurgitation
(MR)
The severity of MR may be overestimated due to the high
ventricular pressure. Surgical intervention on the mitral valve
is generally not necessary in non-severe MR, as long as there
are no morphological leaflet abnormalities (flail leaflet, pro-
laps, signs of endocarditis, post-rheumatic changes) or mitral
annulus dilatation or marked abnormalities of the LV
geometry.
5.4.2. Combination of AS with coronary artery disease (CAD)
Combined AVR and CABG carries a higher risk than isolated
AVR. The operative mortality of AVR alone is approximately
3% and AVRþCABG 4.5–6%. However, AVR late after CABG islantation (TAVI).
art team
tion to the patient’s symptoms, that can be treated only by surgery
ation, short distance between annulus and coronary ostium, and small
ssel size, calcification, and tortuosity)
ible
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 4 1 – e 5 6 e49associated with even more significant risk, including possible
CABG impairment. Patients with moderate AS indicated for
CABG usually benefit from AVR. Also patientso70 years, once
the peak gradient exceeds 30 mm Hg and the progression of
5 mm Hg per year is documented, may benefit from com-
bined surgery. The clinical judgment with the assessment of
individual risk, comorbidities, leaflet calcification and life
expectancy is important. Patients with severe symptomatic
AS and diffuse CAD that cannot be revascularized should not
be denied AVR, in spite of a high risk.Table 11 – Indications for surgery in severe primary
mitral regurgitation.6. Mitral regurgitation (MR)
In Europe, MR is the second most frequent valve disease
requiring surgery. The approach to the treatment of MR has
been redefined as a result of the good results of valve sparing
surgery.
6.1. Primary mitral regurgitation
The most common aetiology of primary MR is degeneration
of valve tissue.
Acute mitral regurgitation has poor prognosis without inter-
vention. It is usually caused by papillary muscle rupture and
presents with pulmonary oedema or shock following acute
myocardial infarction. It may also be caused by infective
endocarditis or trauma. The murmur may be soft or inaud-
ible; colour Doppler flow may underestimate the severity of
the lesion. Urgent echocardiography is important; the diag-
nosis is suggested by hyperdynamic left ventricular function
in the presence of acute heart failure. Urgent surgery is
indicated after stabilisation of haemodynamic status using
an intra-aortic baloon pump, positive inotropic agents and,
when possible, vasodilatators.
Chronic mitral regurgitation should be evaluated by echocar-
diography with the assessment of severity, mechanisms, repair-
ability and consequences of the MR (left atrial volume, left
ventricular size and EF, pulmonary pressure and right ventri-
cular function). The criteria for severity are described in Table 5.
Transoesophageal echocardiography (TOE) and 3-dimensional
echocardiography may provide more information before plan-
ning surgery. The result of mitral valve repair must be assessed
intraoperatively by TOE.
Predictors of poor outcome are symptoms, age, atrial
fibrillation, severity of MR (effective regurgitant orifice area),
pulmonary hypertension, left atrial dilatation, increased left
ventricular end-systolic diameter (LVESD) and low LVEF. Low
plasma natriuretic levels have a high negative predictive
value and may be helpful for the follow-up of asymptomatic
patients. In asymptomatic severe chronic MR the estimated
5-years rates of death from any cause have been reported to
be 2273%, death from cardiac causes 1473%, and cardiac
events 3373%. Indications for surgery are summarized in
Table 11.
6.2. Results of surgery
Mitral valve repair has lower perioperative mortality,
improved survival, better preservation of postoperative LVfunction, and lower long-term mortality compared to valve
replacement. The best results of surgery are observed in
patients with preoperative LVEF460% without LV dilatation
and without symptoms. The development of even mild
symptoms by the time of surgery is associated with deleter-
ious changes in cardiac function after surgery. In MR due to
flail leaflet LVESDZ40 mm (Z22 mm/m2 BSA) has been
Table 12 – Indications for mitral valve surgery in chronic
secondary mitral regurgitation.
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tality with medical treatment as opposed to mitral surgery.
Patients with predictable complex difficult repair should
undergo surgery in experienced centres with high repair rates
and low operative mortality. When repair is not feasible,
mitral valve replacement with preservation of the subvalvu-
lar apparatus is preferred. The operative mortality in mitral
valve repair is reported between 1.6% and 2.1%, in mitral
valve replacement between 4.3% and 7.8%; the rates are
higher with concomitant CABG (4.6–8.3% for repair with
CABG and 11.1–14.5% for replacement with CABG).
6.3. Percutaneous intervention
The only catheter-based procedure, which has been evalu-
ated in organic MR, is the edge-to-edge procedure with
MitraClip. The procedure reduces MR less effectively than
surgery. It may be considered in patients with severe sympto-
matic primary MR, who fulfil the echo criteria for eligibility,
are judged inoperable by a heart team or are at high surgical
risk and have a life expectancy greater than 1 year (class IIb,
level C). Data from EVEREST study and European and USA
registries show procedural success rate around 75% (post-
procedural MRr2þ). It is relatively safe and generally well-
tolerated, even by patients in poor clinical condition. One-
year freedom from death, mitral valve surgery or more than
moderate MR is 55%.
6.4. Medical therapy
There is no evidence to support the use of vasodilators,
including ACE inhibitors, in chronic MR without HF and they
are therefore not recommended in this group of patients.
However, when HF has developed, ACE inhibitors are bene-
ficial and should also be considered in patients with
advanced MR and severe symptoms, who are not suitable
for surgery or when there are still residual symptoms follow-
ing surgery. Beta-blockers and spironolactone should also be
considered as appropriate.
6.5. Secondary mitral regurgitation
In secondary (¼functional) MR, mitral valve leaflets and
chordae are structurally normal and MR results from geome-
trical distortion of the subvalvular apparatus, secondary to
left ventricular enlargement and remodelling. It may be due
to idiopathic cardiomyopathy or coronary artery disease
(termed ‘‘ischaemic MR’’, although this does not imply the
presence of myocardial ischaemia). Secondary MR results from
tethering (apical and lateral papillary muscle displacement,
annular dilatation) and reduced closing forces due to LV
dysfunction (reduced contractility and/or LV dyssynchrony).
The murmur is often soft and unrelated to the severity of
MR. MR is dynamic and its severity changes according to
loading conditions: hypertension, medical therapy, and exer-
cise. Acute pulmonary oedema may result from dynamic
changes in MR and resulting increase in pulmonary vascular
resistance.
Echocardiography differentiates primary and secondary
MR. Because of their prognostic value, lower thresholds ofseverity have been proposed for secondary MR: 20 mm2 for
the effective regurgitant orifice area (EROA) and 30 ml for
regurgitant volume (RV) (Table 5). The dynamic component
may be assessed by exercise echocardiography. An exercise
induced increase of EROA of Z13 mm2 has been shown to be
associated with increase in relative risk of death and hospi-
talisation for cardiac decompensation. In patients with low
LVEF, it is mandatory to assess myocardial viability.
In patients with coronary artery disease, the decision on
whether or not to treat ischaemic MR should be made before
surgery, as general anaesthesia may significantly reduce the
severity of regurgitation.
Patients with chronic ischaemic MR have a poor prognosis;
increasing severity of MR is associated with worse outcome.
The indications for intervention in secondary MR are less
evidence-based than primary MR due to the heterogeneous
data (Table 12). There are no data to support surgical correc-
tion of mild MR.6.6. Results of surgery
Operative mortality is higher than in primary MR and the
long-term prognosis is worse. The preferred surgical proce-
dure remains controversial, because of the persistence and
high recurrence rate of MR after valve repair and the absence
of evidence that surgery prolongs life. Most studies show that
severe ischaemic MR is not improved by revascularisation
alone and persistence of residual MR carries increased
mortality risk.
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sized rigid ring annuloplasty, which confers a low operative
risk, although it carries a high risk of MR recurrence. Numerous
preoperative predictors of recurrent secondary MR after under-
sized annuloplasty have been identified: LVEDD465mm, pos-
terior mitral leaflet angle 4451, distal anterior mitral leaflet
angle4251, systolic tenting area42.5 cm2, coaptation distance
(distance between the annular plane and coaptation point)
410mm, end-systolic interpapillary muscle distance
420mm, and systolic sphericity index 40.7.
No randomised study comparing repair against replace-
ment has been performed comparing repair against replace-
ment. In the most complex high-risk settings, survival after
repair and replacement is similar. A recent meta-analysis of
retrospective studies suggests better short- and long-term
survival after repair. Several techniques have been proposed
to address subvalvular tethering. A recent randomised trial
reports improved survival after ventricular reshaping. The
presence of significant myocardial viability is a predictor of
good outcome after repair combined with bypass surgery.Table 13 – Indications for percutaneous mitral commi-
surotomy (PMC) in mitral stenosis with valve area
r1.5 cm2.6.7. Percutaneous intervention
Percutaneous edge-to-edge mitral valve repair is feasible, at
low procedural risk in patients with secondary MR in the
absence of severe tethering. Patients must fulfil the echo
criteria of eligibility, should be judged inoperable or be at high
surgical risk, and should have life expectancy greater than 1
year. Mitra-Clip may provide short-term improvement in
functional condition and LV function according EVEREST trial
and observational studies.
Data on coronary sinus annuloplasty are limited and most
devices have been withdrawn.6.8. Medical treatment
Optimal medical treatment is mandatory and it should be the
first step in all secondary MR according to the guidelines for
heart failure. Treatment includes ACE inhibitors, beta-blockers,
aldosterone antagonists and diuretics in the presence of fluid
overload. Nitrates may be useful in acute dyspnoea. Left ven-
tricle reverse remodelling may further reduce secondary MR.
Cardiac resynchronization therapy (CRT) may immediately
reduce MR severity through increased closing force and
resynchronisation of papillary muscles.7. Mitral stenosis (MS)
The predominant aetiology is rheumatic fever, which has
greatly decreased in industrialized countries. The main diag-
nostic method is echocardiography with the assessment of
the extent of anatomic lesions as well as consequences of the
MS. MS usually does not have clinical consequences at rest
when valve area is41.5 cm2. A comprehensive assessment of
valve morphology is important for the treatment strategy.
Left atrial thrombus must be excluded by transoesophageal
echcardiography before percutaneous mitral commisurotomy
(PMC). Survival in asymptomatic patients is usually good upto 10 years; symptomatic patients have a poor prognosis
without intervention.
Indications for intervention and the decision between PMC
or surgery are summarized in Tables 13 and 14 and Fig. 2.7.1. Results of PMC
Good initial results, defined as valve area 41.5 cm2 with no
MR42/4, are achieved in over 80%. Emergency surgery is
needed in o1%. Successful PMC reduces embolic risk. Event-
free survival ranges from 30% to 70% after 10–20 years. When
the immediate results are unsatisfactory, surgery is usually
required.7.2. Results of surgery
In current practice surgery for MS is mostly valve replace-
ment in elderly population with unfavourable characteristics
for valve repair. Operative mortality for valve replacement
ranges from 3% to 10%. Closed mitral commissurotomy is still
Fig. 2 – Management of clinically significant mitral stenosis. CI: contraindication, MS: mitral stenosis, PMC: percutaneous
mitral commisurotomy. (a) See Table 13; (b) surgical commisurotomy may be considered by experienced surgical teams or in
patients with contraindication to PMC.
Table 14 – Contraindications to percutaneous mitral commissurotomy.
Mitral valve area 41.5 cm2
Left atrial thrombus
More than mild mitral regurgitation
Severe or bicommissural fusion
Absence of commissural fusion
Severe concomitant aortic valve disease, or severe combined tricuspid stenosis and regurgitation
Concomitant coronary artery disease requiring bypass surgery
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replaced by open mitral commissurotomy using cardiopul-
monary bypass, used mostly in young patients.
7.3. Medical therapy
Diuretics or long-acting nitrates transiently ameliorate dys-
pnoea, beta-blockers or heart-rate regulating calcium chan-
nel blockers can improve exercise tolerance. Anticoagulant
therapy with a target INR 2–3 is indicated in patients with
permanent or paroxysmal atrial fibrillation. In sinus rhythm,
anticoagulation is indicated in the case of prior embolism, or
a thrombus in the left atrium (class I, level of evidence C) and
should be considered in the case of dense spontaneous
echocontrast or enlarged left atrium (diameter 450 mm or
volume 60 ml/m2 recommendation IIa, level C). Antiplatelet
agents are not valid alternatives.8. Tricuspid regurgitation (TR)
TR is most often secondary due to annular dilatation and
increased tethering in right ventricle (RV) in pressure or
volume overload. TR may be well tolerated; clinical signs of
right heart failure are load-dependent.
TR is evaluated by echocardiography. Significant annular
dilatation is defined by a diastolic diameter Z40 mm or
421 mm/m2 BSA in the four-chamber transthoracic view. In
secondary TR coaptation distance 48 mm means significant
tethering (distance between annular plane and the point of
coaptation in mid-systole). Patients with RV systolic dysfunc-
tion have usually tricuspid annular plane systolic excursion
(TAPSE)o15 mm, tricuspid annulus systolic velocityo11 cm/
s, and RV end-systolic area 420 cm2. Magnetic resonance is
preferable for evaluating RV size and function.
Table 15 – Indications for tricuspid valve surgery.
Table 16 – Choice of the aortic/mitral prosthesis in favour
of a mechanical prosthesis.
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overload may result in ventricular dysfunction and irrever-
sible myocardial damage. TR may persist even after success-
ful correction of left-sided lesion. Risk factors are PH,
increased RV pressure and dimension, reduced RV function,
pacemaker leads, severity of annular dilatation and coapta-
tion height.
Valve repair is preferable to valve replacement and should
be performed early enough to avoid irreversible RV dysfunc-
tion (Table 15). The results of a late intervention with RV
dysfunction are poor.
8.1. Results of surgery
Prosthetic ring annuloplasty has better results than suture
annuloplasty with the incidence of residual TR 10% vs 20–35%
at 5 years. Complementary leaflet procedure may be added in
severe leaflet deformation. In more advanced forms of tether-
ing and RV dilatation, valve replacement should be consid-
ered. Large bioprostheses are favoured over mechanical
valves. Adding a tricuspid repair does not increase operative
risk of left-sided surgery. Ten-year survival ranges from 30%
to 50%, the predictors being preoperative functional class, LV
and RV dysfunction, and prosthetic complications.
8.2. Medical therapy
Diuretics reduce congestion.9. Tricuspid stenosis (TS)
TS is mostly of rheumatic origin, and almost always is asso-
ciated with left-sided lesions. Significant TS has usually a mean
gradient of Z5mm Hg at normal heart rate. Replacement with
biological valves is preferred over mechanical valves, valve
repair, or percutaneous baloon intervention, which usually
induces significant TR. Diuretics have limited efficacy.10. Combined and multiple valve diseases
It is necessary to consider the interaction between different
lesions. As an example associated MR may underestimate the
severity of AS due to decreased stroke volume. This under-
lines the need of diagnostic methods less dependent on
loading conditions, such as planimetry. Intervention can be
considered for non-severe multiple lesions with symptoms or
LV impairment.11. Prosthetic valves
11.1. Choice of prosthetic valve
Prosthetic valves are mechanical (bileaflet or older single tilting
disc) or biological (homografts, pulmonary autografts, porcine,
pericardial bovine or equine). Xenografts are stented or stentless,
incoming technology are suturless bioprostheses. Transcatheter-
implantable are pericardial bioprosthesis inserted into bare-
metal baloon-expanding stent or nitinol self-expanding stent.
Table 18 – Indications for antithrombotic therapy after
valvular surgery.
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(SVD) of homografts is 11 years in a 20-years-old patient and 25
years in a 65-years-old patient. The main indication for homo-
grafts is acute infective endocarditis with perivalvular lesion. In
practice, the majority of patients have mechanical prostheses
or stented bioprostheses. No differences were found between
both groups in survival, thromboembolism or bleeding rates in
a randomised trial in patients 55–70 years old. There was a
higher rate of valve failure and reoperations in bioprostheses
group. The risk of SVD decreases with age, and is higher in
mitral position. Treating bioprosthetic failure by transcatheter
valve-in-valve implantation has been shown to be feasible; it is
currently limited to unoperable or high-risk patients.
Even if SVD is accelerated in chronic renal failure, the
increased risk of complications with mechanical prosthesis
favours the choice of bioprosthesis.
The high risk of pregnancy with mechanical valve and the
low risk of elective reoperation allow the choice of bioprosth-
esis in women planning pregnancy.
The inconvenience of mechanical prostheses can be mini-
mized by self-management of the anticoagulation therapy. If
the valve prosthesis–patient ratio is expected to beo0.65 cm2/
m2 BSA (¼patient–prosthesis mismatch), enlargement of the
annulus to allow placement of a larger prosthesis may be
considered. The prosthesis choice should be individualized
and discussed with the informed patient (Tables 16 and 17).11.2. Management after valve replacement
All patients after valve surgery require lifelong follow-up by a
cardiologist, endocarditis prophylaxis and transoesophageal
echo in suspected prosthetic dysfunction, endocarditis or
poor transthoracic image. Cinefluoroscopy and multisliced
CT may be helpful in suspected valve thrombus or pannus.Table 17 – Choice of the aortic/mitral prosthesis in favour
of a bioprosthesis.
Table 19 – Target international normalized ratio (INR) for
mechanical prosthesis.
Patient-related factorsb
Prosthesis thrombogenicitya No risk factor Risk factorZ1
Low 2.5 3.0
Medium 3.0 3.5
High 3.5 4.0
a Low¼Carbomedics, Medtronic Hall, St Jude Medical, ON-X;
medium¼other bileaflet valves; high¼Lillehei-Kaster, Omnis-
cience, Starr-Edwards, Bjork-Shiley and other tilting disc valves.
b Patient-related risk factors: mitral or tricuspid valve replace-
ment, previous thromboembolism, atrial fibrillation, mitral ste-
nosis of any degree, left ventricular ejection fraction o35%.
Fig. 3 – Management of left-sided obstructive prosthetic thrombosis. IV UFH: intravenous unfractionated heparin; TOE:
transoesophageal echocardiography; TTE: transthoracic echocardiography. (a) Risks and benefits of both treatments should
be individualized. The presence of a first-generation prosthesis is an incentive to surgery.
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is given in Tables 18 and 19. The substitution of vitamin K
antagonists by direct oral inhibitors of factor IIa or Xa is not
recommended, because specific clinical trials in such patients
are not available at this time. The low-molecular-weight
heparin (LMWH) seems to be effective, but there is a lack of
randomized controlled trials. If it is used, it should be
monitored by antiXa activity with a target of 0.5–1.0 U/ml.
LMWH is contraindicated in severe renal dysfunction. Despite
the lack of evidence, a combination of low-dose aspirin and a
thienopyridine is used early after TAVI or MitraClip, followed
by aspirin or a thienopyridine alone. When added to antic-
oagulation, antiplatelet agents increase the risk of bleeding
and the dose should be low (e.g. aspirinr100 mg daily). Bare-
metal stents should be preferred over drug-eluting stents in
patients with mechanical prosthesis to shorten the use of
triple therapy to 1 month.1According to the ESC Guidelines on the management of
cardiovascular diseases during pregnancy (2011).11.3. Management of valve thrombosis
Urgent or emergency valve replacement is recommended for
obstructive thrombosis in critically ill patients without ser-
ious comorbidity (Figs. 3 and 4).
Fibrinolysis should be considered in critically ill unlikely to
survive surgery, without the possibility of transfer to surgery,
and in thrombosis of tricuspid or pulmonary valves because
of the higher success rate and lower risk of systemicembolism. In haemodynamically unstable patient, a short
protocol is recommended (Table 20).
The prognosis is favourable with medical therapy in
most small thrombi (o10mm); surgery should be considered
for large (Z10mm) non-obstructive thrombus which persists,
despite optimal anticoagulation or complication by embolism.12. Management during non-cardiac surgery
Cardiovascular morbidity and mortality are increased in
patients with VHD who undergo non-cardiac surgery. The
details can be found in specific ESC guidelines.13. Management during pregnancy
The management of VHD during pregnancy is detailed in the
ESC Guidelines on pregnancy. Maternal mortality is estimated
1–4% in women with mechanical valves. During the first
trimester there is a choice between vitamin K antagonists
(in class IIa if the dose of warfarin is o5 mg/day)1, UFH or
LMWH. Vitamin K antagonists are preferred during the
second and third trimester until the 36th week, when they
should be replaced by heparin (class I, level of evidence C).
Table 20 – Short protocol of fibrinolysis in haemodynamically unstable patientsa.
Recombinant tissue plasminogen activator 10 mg bolusþ90 mg in 90 min with UFH
Streptokinase 1,500,000 U in 60 min without UFH
UFH: Unfractioned heparin.
a Longer durations of infusions can be used in stable patients.
Fig. 4 – Management of left-sided non-obstructive prosthetic thrombosis. TE: thromboembolism; TOE: transoesophageal
echocardiography; TTE: transthoracic echocardiography.
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